Please use this identifier to cite or link to this item: https://doi.org/10.1002/ehf2.12228
DC FieldValue
dc.titleChronic obstructive pulmonary disease and β-blocker treatment in Asian patients with heart failure
dc.contributor.authorKubota Y.
dc.contributor.authorTay W.T.
dc.contributor.authorAsai K.
dc.contributor.authorMurai K.
dc.contributor.authorNakajima I.
dc.contributor.authorHagiwara N.
dc.contributor.authorIkeda T.
dc.contributor.authorKurita T.
dc.contributor.authorTeng T.-H.K.
dc.contributor.authorAnand I.
dc.contributor.authorLam C.S.P.
dc.contributor.authorShimizu W.
dc.contributor.authoron behalf of the ASIA-HF Study investigators
dc.date.accessioned2019-03-06T07:53:00Z
dc.date.available2019-03-06T07:53:00Z
dc.date.issued2018
dc.identifier.citationKubota Y., Tay W.T., Asai K., Murai K., Nakajima I., Hagiwara N., Ikeda T., Kurita T., Teng T.-H.K., Anand I., Lam C.S.P., Shimizu W., on behalf of the ASIA-HF Study investigators (2018). Chronic obstructive pulmonary disease and β-blocker treatment in Asian patients with heart failure. ESC Heart Failure 5 (2) : 297-305. ScholarBank@NUS Repository. https://doi.org/10.1002/ehf2.12228
dc.identifier.issn20555822
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/152051
dc.description.abstractAims: Chronic obstructive pulmonary disease (COPD) and heart failure (HF) are increasingly frequent in Asia and commonly coexist in patients. However, the prevalence of COPD among Asian patients with HF and its impact on HF treatment are unclear. Methods and results: We compared clinical characteristics and treatment approaches between patients with or without a history of COPD, before and after 1:2 propensity matching (for age, sex, geographical region, income level, and ethnic group) in 5232 prospectively recruited patients with HF and reduced ejection fraction (HFrEF, <40%) from 11 Asian regions (Northeast Asia: South Korea, Japan, Taiwan, Hong Kong, and China; South Asia: India; Southeast Asia: Thailand, Malaysia, Philippines, Indonesia, and Singapore). Among the 5232 patients with HFrEF, a history of COPD was present in 8.3% (n = 434), with significant variation in geography (11.0% in Northeast Asia vs. 4.7% in South Asia), regional income level (9.7% in high income vs. 5.8% in low income), and ethnicity (17.0% in Filipinos vs. 5.2% in Indians) (all P < 0.05). Use of mineralocorticoid receptor antagonists and diuretics was similar between groups, while usage of all β-blockers was lower in the COPD group than in the non-COPD group in the overall (66.3% vs. 79.9%) and propensity-matched cohorts (66.3% vs. 81.7%) (all P < 0.05). A striking exception was the Japanese cohort in which β-blocker use was high in COPD and non-COPD patients (95.2% vs. 91.2%). Conclusions: The prevalence of COPD in HFrEF varied across Asia and was related to underuse of β-blockers, except in Japan. © 2017 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
dc.publisherWiley-Blackwell
dc.sourceScopus
dc.subjectChronic obstructive pulmonary disease
dc.subjectHeart failure
dc.subjectβ-Blocker
dc.typeArticle
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.1002/ehf2.12228
dc.description.sourcetitleESC Heart Failure
dc.description.volume5
dc.description.issue2
dc.description.page297-305
dc.published.statepublished
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
ehf2.12228.pdf135.2 kBAdobe PDF

OPEN

NoneView/Download

Page view(s)

25
checked on Jul 18, 2019

Download(s)

2
checked on Jul 18, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.